Day: March 27, 2024

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

Written by Customer Service on March 27, 2024. Posted in Mergers And Acquisitions.

PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) — Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally. Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content. It applies its expertise and unique approaches to deliver quality medical writing output....

ARGAN delivered a 4,600 sq.m, Aut0nom®-labelled distribution centre to DSV in Normandie

Written by Customer Service on March 27, 2024. Posted in Public Companies.

Press release – Neuilly-sur-Seine, Wednesday, March 27, 2024 – 5.45 pm ARGAN delivered a 4,600 sq.m, Aut0nom® -labelled distribution centre to DSV in Normandie Photo credit: Argan After works that lasted for 10 months, DSV Road teams are now operating on the new distribution platform located in Eslettes (76), near Rouen. This 4,600 sq.m building, which was developed by ARGAN, is Aut0nom®-labelled, i.e. an “in-use Net Carbon Zero warehouse”. DSV is operating this platform through its DSV Road division, as part of a nine-year fixed-term lease. This is the second time that DSV and ARGAN – which already owns the Gennevilliers buildings where the DSV French headquarters are located – work together. DSV is a front-running international company, which delivers transportation and logistics services. Aut0nom®, an in-use Carbon Zero site A particular...

Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer

Written by Customer Service on March 27, 2024. Posted in Public Companies.

Strasbourg, France, March 27, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Lucie Larguier as Chief Financial Officer (CFO), effective immediately. Formerly VP, Corporate Communication and Investor Relations at Transgene, in her new role as CFO, Lucie Larguier will be responsible for all aspects of the Company’s financial strategy, management and operations to ensure efficient delivery of Transgene’s innovative immunotherapy pipeline. Lucie succeeds Arnaud Dubarry who has stepped down to pursue other opportunities. Already a member of the executive management committee, Lucie Larguier brings a comprehensive, cross-functional view of the Company’s operations and finances as well as a deep...

KLÉPIERRE: AVAILABILITY OF 2023 UNIVERSAL REGISTRATION DOCUMENT

Written by Customer Service on March 27, 2024. Posted in Public Companies.

REGULATED RELEASE AVAILABILITY OF 2023 UNIVERSAL REGISTRATION DOCUMENT Paris – March 27, 2024 Klépierre has filed today the French version of its universal registration document relating to fiscal year 2023, prepared in ESEF format (European Single Electronic Format) with the Autorité des marchés financiers (“AMF”), under the registration number D.24-0185. It can be read or downloaded on the websites of:Klépierre: www.klepierre.com, in the section Finance/Publications/Annual and semi-annual reports; the AMF: www.amf-france.org.An English version of the universal registration document is also available online. The French version of the universal registration document as well as its English translation are also available to the public, free of charge upon request:By mail:KlépierreInvestor Relations26, boulevard des Capucines75009...

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

2023 Full-year results and business updateLead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 months. New leadership team focused on successfully delivering TG4050 and portfolio products to patients. Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.Conference call scheduled today at 6 p.m. CET (in English). See details below. Strasbourg, France, March 27, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2023, and provides an update on its...

Cegedim Full year 2023 results: Revenue and recurring operating income both up

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

PRESS RELEASEQuarterly financial information as of December 31, 2023IFRS – Regulated information – Audited Full year 2023 results: Revenue and recurring operating income both up2023 revenues rose 10.9% to €616.0 million Recurring operating income(1) rose 23.4% to €31.7 millionBoulogne-Billancourt, France, March 27, 2024, after the market close Cegedim generated consolidated revenues of €616.0 million in 2023, an increase of 10.9% as reported and 10.8% like for like(2) compared with the previous year, and recurring operating income(1) came to €31.7 million, a 23.4% increase. Consolidated income statement 2023 2022 Change (in €m) (in %) (in €m) (in %) (in %)Revenues 616.0 100.0% 555.2 100.0% 10.9%EBITDA(1) 108.8 17.7% 96.2 17.3% 13.1%Depreciation & amortization -77.2 -12.5% -70.5 -12.7% 9.4%Recurring...

Sidetrade’s 2023 Results: Robustness of the profitable growth model confirmed

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Robustness of the profitable growth model confirmedStrong revenue growth, up 20%, with SaaS subscriptions up 23% at constant exchange rates CreditPoint Software, an accretive acquisition, now fully operational Operating profit up 58% to €5.8 million vs. €3.7 million in 2022 Operating margin up sharply to 13% vs. 10% in 2022 Net profit up 67% to €5.6 million vs. €3.4 million in 2022 Operating cash flow generation at €8.7 million Dual recognition for CSR commitment: rated Gold by EthiFinance and Silver by EcoVadisSidetrade, the global leader in AI-powered Order-to-Cash applications, today announces a 20% increase in revenue for 2023 at constant exchange rates (up 19% on a reported basis), with a surge in operating profit, up 58% to €5.8 million, as well as in operating margin at 13%, and in net profit, up 67% to €5.6 million. Olivier...

Press release – SPIE signs an agreement to acquire MBG energy in Germany

Written by Customer Service on March 27, 2024. Posted in Mergers And Acquisitions.

Cergy, March 27th, 2024 – SPIE, the independent European leader in multi-technical services in the areas of energy and communications, announces the signature of an agreement to acquire c.75% of MBG energy GmbH in Germany. MBG energy GmbH is a provider of engineering, procurement and construction (EPC) services for thephotovoltaic roll-out mainly for rooftop installation on buildings in North-Eastern Germany. The company, headquartered in Berlin, was founded in 2018 and employs 47 employees. The company generated a revenue of approximately 15 million euros in 2023. With this acquisition, SPIE will strengthen its position in the fast-growing photovoltaic roll-out market and gain competences in that field in a context of the adoption by the European legislators of the EU Solar Standard within the European Performance of Buildings Directive....

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Written by Customer Service on March 27, 2024. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has closed on its agreement with Seyltx Inc. (“Seyltx”), a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 (“Ifenprodil”) research program for the purchase price of USD $2M cash and a 20% common share equity position in Seyltx. The Company previously announced on November 22, 2023 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program. Ifenprodil is an N-methyl-D-aspartate (“NMDA”) receptor antagonist specifically targeting the NMDA type subunit 2B (GluN2B), which prevents glutamate...

TEN Ltd. Reports Record Profits for Year-End and Fourth Quarter 2023 Results and Dividend of $0.60 per Common Share

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Record annual profits in excess of $300 million – an increase of 60% – EPS of $9.93 EBITDA of $490 million 100% increase of common dividend Dynamic growth and fleet renewal with green ship initiative Market fundamentals remain strong ATHENS. Greece, March 27, 2024 (GLOBE NEWSWIRE) — TEN, Ltd. (TEN) (NYSE: TNP) (the “Company”) reports results (unaudited) for the fourth quarter and the year ended December 31, 2023. FINANCIAL RESULTS FOR THE YEAR 2023TEN celebrated its 30th year as a public company, with another record year performance. In 2023 it generated $890 million in revenues resulting to a net income of $327 million before impairment charges, a significant increase from last year. Adjusted EBITDA for the year reached $490 million, $95 million higher than in 2022, a 24% increase. Average TCE per ship per day for 2023...

Day: March 27, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice